

May 19, 2023

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub: Outcome of the Board Meeting held on 19th May, 2023

Pursuant to Regulation 30 of the SEBI LODR, Regulations 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee & Audit Committee, Board at its meeting held today, has approved the following:

a) Re-appointment of Mr. V.S. Mani (DIN- 01082878) as Executive Director & Global Chief Financial Officer of the Company for a further period of 3 years with effect from 29th May, 2023.

Further, the Board of Directors have decided to seek the consent of the members of the Company by way of Resolution through Postal Ballot Process for:

a) Re-appointment of Mr. V.S. Mani (DIN- 01082878) as Executive Director & Global Chief Financial Officer of the Company for a further period of 3 years with effect from 29th May, 2023.

The Board of Directors have appointed Mr. Surjan Singh Rauthan, Practicing Company Secretary, who has given his consent to act as the scrutinizer, for conducting the Postal Ballot process, in a fair and transparent manner.

Further, this is to confirm that Mr. V.S. Mani, Executive Director & Global Chief Financial Officer is not debarred from holding the office pursuant to any SEBI order or any such authority respectively.



Brief details of Mr. V.S. Mani, in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 is enclosed as Annexure I.

You are requested to take the same on record.

Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited

Harish Kuber Company Secretary & Compliance Officer

Encl: As above

Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)



<u>Annexure I</u>

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sr. No.	Particulars	Details
1.	Name & Designation of Director	Mr. V.S. Mani (Executive Director & Global Chief Financial Officer)
2.	Reason for change	Re-appointment
3.	Date of appointment & term of appointment	Effective date of re-appointment - From 29th May, 2023 for a further period of 3 years
4.	Brief Profile	Mr. V.S. Mani (DIN 01082878) is a qualified Chartered Accountant and holds a Bachelor's degree in Commerce from Mumbai University. He leads the organization's worldwide Finance operations, as well as Legal and Secretarial functions. Mr. Mani was associated with Cipla Limited for over fourteen years across two stints. His last stint at Cipla was as their Global Chief Finance Officer. Mr. Mani has also held various financial leadership roles at Wockhardt, Bhartiya Group, VIP Industries and Glenmark Pharmaceuticals Limited. Along with a deep understanding of the Pharmaceutical industry, he has over thirty years of rich functional experience including Treasury, Taxation (Direct, Indirect & International), Accounting, Financial Planning & Analysis, Secretarial, Legal, Audits(Internal & Statutory), Risk Management & Investor Relations.
5.	Disclosure of relationships between directors (in case of appointment of a director)	None.